1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
10x Genomics, Inc.

10x Genomics, Inc.

TXG
10x Genomics, Inc.US flagNASDAQ Global Select
28.84
USD
-0.21
- -
3.66BMarket Cap

Total Valuation

10x Genomics, Inc. carries a market capitalization of 3.66B, placing it among publicly traded companies globally. Its enterprise value stands at 2.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.66B
Enterprise Value2.22B

Share Statistics

10x Genomics, Inc. currently has 128.99M shares outstanding.

Shares Outstanding128.99M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 4.19, and the price-to-book ratio stands at -1.76.

PE RatioN/A
PS Ratio4.19
PB Ratio-1.76
P/TBV Ratio3.57
P/FCF Ratio20.07
P/OCF Ratio20.95

Enterprise Valuation

EV / Sales3.48
EV / EBITDAN/A
EV / EBITN/A
EV / FCF16.63

Financial Position

10x Genomics, Inc. maintains a current ratio of 5.90, meaning it holds 5.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.99, indicating elevated leverage, while an interest coverage ratio of -11,163.67 demonstrates limited ability to service its debt obligations.

Current Ratio5.90
Quick Ratio5.25
Debt / Equity9.99
Debt / EBITDA-2.43
Interest Coverage-11,163.67

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-2.36
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)6.33
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.03

Taxes

Over the trailing twelve months, 10x Genomics, Inc. has paid 3.41M in income taxes, reflecting an effective tax rate of 6.65.

Income Tax3.41M
Effective Tax Rate6.65

Stock Price Statistics

10x Genomics, Inc.'s stock has gained approximately 161.94369% over the past 52 weeks. The 50-day moving average sits at 24.49, while the 200-day moving average is 18.73.

Beta (5Y)N/A
52-Week Price Change161.94369%
50-Day Moving Average24.49
200-Day Moving Average18.73
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, 10x Genomics, Inc. generated 638.78M in revenue and converted that into -22.66M in net income, yielding earnings per share of -0.18. EBITDA reached -33.49M, while operating income came in at -79.40M.

Revenue638.78M
Gross Profit444.61M
Operating Income-79.40M
Pretax Income-19.25M
Net Income-22.66M
EBITDA-33.49M
EBIT-79.40M
Earnings Per Share (EPS)-0.18

Balance Sheet

10x Genomics, Inc. holds 539.85M in cash and equivalents against 81.39M in total debt, resulting in a net debt position of -490.28M. Total book value stands at -1.52B, with working capital of 556.14M providing operational flexibility.

Cash & Cash Equivalents539.85M
Total Debt81.39M
Net Debt-490.28M
Equity (Book Value)-1.52B
Book Value Per Share-12.08
Working Capital556.14M

Cash Flow

10x Genomics, Inc. produced 127.82M in operating cash flow over the past twelve months. After subtracting -5.64M in capital expenditures, free cash flow totaled 122.18M - equivalent to 0.97 per share.

Operating Cash Flow127.82M
Capital Expenditures-5.64M
Free Cash Flow122.18M
FCF Per Share0.97

Margins

10x Genomics, Inc. operates with a gross margin of 69.60, reflecting its pricing power and cost economics. The operating margin of -12.43 and net profit margin of -3.55 provide insight into operational efficiency.

Gross Margin69.60
Operating Margin-12.43
Pretax Margin-3.01
Profit Margin-3.55
EBITDA Margin-5.24

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.08
FCF Yield4.98

Stock Splits

10x Genomics, Inc.'s most recent stock split took place on July 17, 2006 with a 2:1 split ratio.

Last Split Date7/17/2006
Split Ratio2:1

Scores

10x Genomics, Inc. posts an Altman Z-Score of 6.83, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.83